Replication-Defective Adenovirus Serotype 5 Vectors Elicit Durable Cellular and Humoral Immune Responses in Nonhuman Primates
Sampa Santra,Michael S. Seaman,Ling Xu,Dan H. Barouch,Carol I. Lord,Michelle A. Lifton,Darci A. Gorgone,Kristin Beaudry,Krisha Svehla,Brent Welcher,Bimal K. Chakrabarti,Yue Huang,Zhi Yong Yang,John R. Mascola,Gary J. Nabel,Norman L. Letvin,Norman L. Letvin +16 more
TLDR
Administration of ADV5-based vectors in DNA-primed subjects may be a preferred use of this vaccine modality for generating long-term immune protection.Abstract:
The magnitude and durability of immune responses induced by replication-defective adenovirus serotype 5 (ADV5) vector-based vaccines were evaluated in the simian-human immunodeficiency virus/rhesus monkey model. A single inoculation of recombinant ADV5 vector constructs induced cellular and humoral immunity, but the rapid generation of neutralizing anti-Ad5 antibodies limited the immunity induced by repeated vector administration. The magnitude and durability of the immune responses elicited by these vaccines were greater when they were delivered as boosting immunogens in plasmid DNA-primed monkeys than when they were used as single-modality immunogens. Therefore, administration of ADV5-based vectors in DNA-primed subjects may be a preferred use of this vaccine modality for generating long-term immune protection.read more
Citations
More filters
Journal ArticleDOI
Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D
Peter Abbink,Angelique A. C. Lemckert,Bonnie A. Ewald,Diana M. Lynch,Matthew Denholtz,Shirley Smits,Lennart Holterman,Irma Damen,Ronald Vogels,Anna R. Thorner,Kara L. O'Brien,Angela Carville,Keith G. Mansfield,Jaap Goudsmit,Menzo J. E. Havenga,Dan H. Barouch +15 more
TL;DR: The construction of three novel rAd vector systems from Ad26, Ad48, and Ad50 are described and a detailed comparison of multiple rAd vectors from subgroups B and D is reported, which substantially expand the portfolio of rare serotype r adenovirus serotype vectors that may prove useful as vaccine vectors for the developing world.
Journal ArticleDOI
Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys
Jinyan Liu,Kara L. O'Brien,Diana M. Lynch,Nathaniel L. Simmons,Annalena La Porte,Ambryice M. Riggs,Peter Abbink,Rory Coffey,Lauren E. Grandpre,Michael S. Seaman,Gary Landucci,Donald N. Forthal,David C. Montefiori,Angela Carville,Keith G. Mansfield,Menzo J. E. Havenga,Maria G. Pau,Jaap Goudsmit,Dan H. Barouch +18 more
TL;DR: It is demonstrated that durable partial immune control of a pathogenic SIV challenge for more than 500 days can be achieved by a T-cell-based vaccine in Mamu-A*01-negative rhesus monkeys in the absence of a homologous Env antigen.
Journal ArticleDOI
Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys.
Norman L. Letvin,John R. Mascola,Yue Sun,Darci A. Gorgone,Adam P. Buzby,Ling Xu,Zhi Yong Yang,Bimal K. Chakrabarti,Srinivas S. Rao,Jörn E. Schmitz,David C. Montefiori,Brianne R. Barker,Fred L. Bookstein,Gary J. Nabel +13 more
TL;DR: Although these monkeys demonstrated a reduction in viremia restricted to the early phase of SIV infection, they showed a prolonged survival that could be predicted by the magnitude of the vaccine-induced cellular immune response, which should guide the evaluation of AIDS vaccines in humans.
Journal ArticleDOI
Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates
Ulrike Wille-Reece,Barbara J. Flynn,Karin Loré,Richard A. Koup,Aaron P. Miles,Allan Saul,Ross M. Kedl,Joseph J. Mattapallil,Walter R. Weiss,Mario Roederer,Robert A. Seder +10 more
TL;DR: In animals vaccinated with HIV Gag protein/Montanide and CpG ODN or the TLR7/8 agonist, the presence and type of TLR adjuvant used during primary immunization conferred stability and dramatically influenced the magnitude and quality of the Th1 and CD8+ T cell responses after the rAD-Gag boost.
Journal ArticleDOI
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.
Frances Priddy,Deborah D. Brown,James G. Kublin,Kathleen Monahan,David Wright,Jacob Lalezari,Steven Santiago,Michael Marmor,Michelle Lally,Richard M. Novak,Stephen J. Brown,Priya Kulkarni,Sheri Dubey,Lisa S. Kierstead,Danilo R. Casimiro,Robin Mogg,Mark J. DiNubile,John W. Shiver,Randi Y. Leavitt,Michael N. Robertson,Devan V. Mehrotra,Erin Quirk +21 more
TL;DR: The vaccine was generally well tolerated and induced cell-mediated immune responses against human immunodeficiency virus type 1 peptides in most healthy adults and vaccination in a proof-of-concept trial with use of this vaccine was discontinued because of lack of efficacy.
References
More filters
Journal ArticleDOI
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
John W. Shiver,Tong-Ming Fu,Ling Chen,Danilo R. Casimiro,Mary-Ellen Davies,Robert K. Evans,Zhiqiang Zhang,Adam J. Simon,Wendy L. Trigona,Sheri Dubey,Lingyi Huang,Virginia Harris,Romnie Long,Xiaoping Liang,Larry Handt,William A. Schleif,Lan Zhu,Daniel C. Freed,Natasha Persaud,Liming Guan,Kara Punt,Aimin Tang,Minchun Chen,Keith A. Wilson,Kelly B. Collins,Gwendolyn J. Heidecker,V. Rose Fernandez,Helen C. Perry,Joseph G. Joyce,Karen M. Grimm,James C. Cook,Paul M. Keller,Denise S. Kresock,Henryk Mach,Robert D. Troutman,Lynne Isopi,Donna M. Williams,Zheng Xu,Kathryn E. Bohannon,David B. Volkin,David C. Montefiori,Ayako Miura,Georgia R. Krivulka,Michelle A. Lifton,Marcelo J. Kuroda,Jörn E. Schmitz,Norman L. Letvin,Michael J. Caulfield,Andrew J. Bett,Rima Youil,David C. Kaslow,Emilio A. Emini +51 more
TL;DR: The replication-defective adenovirus is a promising vaccine vector for development of an HIV-1 vaccine and elicited by a replication-incompetent Ad5 vector, used either alone or as a booster inoculation after priming with a DNA vector.
Journal ArticleDOI
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.
Rama Rao Amara,Francois Villinger,John D. Altman,Shari L. Lydy,Shawn P. O'Neil,Silvija I. Staprans,David C. Montefiori,Yan Xu,James G. Herndon,Linda S. Wyatt,Maria Angelito Candido,Natalia Kozyr,Patricia L. Earl,James M. Smith,Hak-Ling Ma,Hak-Ling Ma,Bennett D. Grimm,Michael L. Hulsey,Joseph I. Miller,Harold M. McClure,Janet M. McNicholl,Bernard Moss,Harriet L. Robinson +22 more
TL;DR: DNA priming followed by a recombinant modified vaccinia Ankara (rMVA) booster controlled a highly pathogenic immunodeficiency virus challenge in a rhesus macaque model, providing hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the acquired immune deficiency syndrome epidemic.
Journal ArticleDOI
Control of Viremia and Prevention of Clinical AIDS in Rhesus Monkeys by Cytokine-Augmented DNA Vaccination
Dan H. Barouch,Sampa Santra,Jörn E. Schmitz,Marcelo J. Kuroda,Tong-Ming Fu,Wendeline Wagner,Miroslawa Bilska,Abie Craiu,Xin Xiao Zheng,Georgia R. Krivulka,Kristin Beaudry,Michelle A. Lifton,Christine E. Nickerson,Wendy L. Trigona,Kara Punt,Dan C. Freed,Liming Guan,Sheri Dubey,Danilo R. Casimiro,Adam J. Simon,Mary-Ellen Davies,Michael Chastain,Terry B. Strom,Rebecca Gelman,David C. Montefiori,Mark G. Lewis,Emilio A. Emini,John W. Shiver,Norman L. Letvin +28 more
TL;DR: The protective efficacy of vaccine-elicited immune responses against a pathogenic SHIV-89.6P challenge in rhesus monkeys is reported, with no evidence of clinical disease or mortality after challenge.
Journal ArticleDOI
Development of a preventive vaccine for Ebola virus infection in primates
TL;DR: A combination of DNA immunization and boosting with adenoviral vectors that encode viral proteins generated cellular and humoral immunity in cynomolgus macaques demonstrates that it is possible to develop a preventive vaccine against Ebola virus infection in primates.
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
Rama Rao Amara,Francois Villinger,John D. Altman,Shari L. Lydy,Shari L. Lydy,Shawn P. O'Neil,Shawn P. O'Neil,Silvija I. Staprans,David C. Montefiori,Yan Xu,James G. Herndon,Linda S. Wyatt,Maria Angelito Candido,Natalia L. Kozyr,Patricia L. Earl,James M. Smith,James M. Smith,Hak-Ling Ma,Hak-Ling Ma,Bennett D. Grimm,Michael L. Hulsey,Harold M. McClure,Janet M. McNicholl,Bernard Moss,Harriet L. Robinson,Harriet L. Robinson +25 more
TL;DR: DNA priming followed by a recombinant modified vaccinia Ankara (rMVA) booster has controlled a highly pathogenic immunodeficiency virus challenge in a Rhesus macaque model, providing hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the AIDS epidemic.
Related Papers (5)
Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
John W. Shiver,Tong-Ming Fu,Ling Chen,Danilo R. Casimiro,Mary-Ellen Davies,Robert K. Evans,Zhiqiang Zhang,Adam J. Simon,Wendy L. Trigona,Sheri Dubey,Lingyi Huang,Virginia Harris,Romnie Long,Xiaoping Liang,Larry Handt,William A. Schleif,Lan Zhu,Daniel C. Freed,Natasha Persaud,Liming Guan,Kara Punt,Aimin Tang,Minchun Chen,Keith A. Wilson,Kelly B. Collins,Gwendolyn J. Heidecker,V. Rose Fernandez,Helen C. Perry,Joseph G. Joyce,Karen M. Grimm,James C. Cook,Paul M. Keller,Denise S. Kresock,Henryk Mach,Robert D. Troutman,Lynne Isopi,Donna M. Williams,Zheng Xu,Kathryn E. Bohannon,David B. Volkin,David C. Montefiori,Ayako Miura,Georgia R. Krivulka,Michelle A. Lifton,Marcelo J. Kuroda,Jörn E. Schmitz,Norman L. Letvin,Michael J. Caulfield,Andrew J. Bett,Rima Youil,David C. Kaslow,Emilio A. Emini +51 more
Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.
Rama Rao Amara,Francois Villinger,John D. Altman,Shari L. Lydy,Shawn P. O'Neil,Silvija I. Staprans,David C. Montefiori,Yan Xu,James G. Herndon,Linda S. Wyatt,Maria Angelito Candido,Natalia Kozyr,Patricia L. Earl,James M. Smith,Hak-Ling Ma,Hak-Ling Ma,Bennett D. Grimm,Michael L. Hulsey,Joseph I. Miller,Harold M. McClure,Janet M. McNicholl,Bernard Moss,Harriet L. Robinson +22 more
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity
Diane M. Roberts,Anjali Nanda,Menzo J. E. Havenga,Peter Abbink,Diana M. Lynch,Bonnie A. Ewald,Jinyan Liu,Anna R. Thorner,Patricia E. Swanson,Darci A. Gorgone,Michelle A. Lifton,Angelique A. C. Lemckert,Lennart Holterman,Bing Chen,Athmanundh Dilraj,Angela Carville,Keith G. Mansfield,Jaap Goudsmit,Dan H. Barouch +18 more